HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Viral hepatitis E — Clinical Guidelines

Overview

Hepatitis E virus (HEV) infection is an emerging zoonotic viral disease that poses an international public health challenge 4. Both Hepatitis A (HAV) and HEV are considered major public health threats worldwide, with an increasing number of cases reported in developed countries 3.

Diagnosis

HEV testing is necessary in hospitalized patients with chronic liver disease (CLD) due to the high prevalence of HEV infection observed in this group 1.

Management

No specific management strategies are detailed in the provided abstracts.

Special Populations

In individuals with underlying chronic liver disease (CLD), HEV infection can trigger acute-on-chronic liver failure 1.

The rates of liver failure and mortality in CLD patients with HEV superinfection are significantly higher, particularly in cirrhotic patients 1.

HEV superinfection significantly increases the risk of liver failure and mortality in CLD patients 1.

Key Recommendations

HEV testing should be performed in hospitalized patients with chronic liver disease 1. (Evidence: Moderate)

Public health authorities should prioritize facing challenges regarding the prevalence of HAV and HEV and implement control strategies to prevent outbreaks 3. (Evidence: Moderate)

Vaccinating children and adopting sanitary measures are essential for HAV disease prevention, and vaccinating at-risk groups may further reduce disease burden 2. (Evidence: Moderate)

References

1 Qiu LX, Huang Y, Quan JL, Bi ZF, Zhong GH, Wang JY et al.. Prognosis of hepatitis E infection in patients with chronic liver disease: A meta-analysis. Journal of viral hepatitis 2023. link 2 Badur S, Öztürk S, AbdelGhany M, Khalaf M, Lagoubi Y, Ozudogru O et al.. Hepatitis A in the Eastern Mediterranean Region: a comprehensive review. Human vaccines & immunotherapeutics 2022. link 3 Chatziprodromidou IP, Dimitrakopoulou ME, Apostolou T, Katopodi T, Charalambous E, Vantarakis A. Hepatitis A and E in the Mediterranean: A systematic review. Travel medicine and infectious disease 2022. link 4 Raji YE, Toung OP, Mohd Taib N, Sekawi ZB. A systematic review of the epidemiology of Hepatitis E virus infection in South - Eastern Asia. Virulence 2021. link

Viral hepatitis E